The Global Alzheimer’s Platform Foundation, (GAP) is releasing the first results from the Bio-Hermes-001 Study.
NewAmsterdam says former Amgen cardio drug reduces heart disease risk factor
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS